A. Bischof

590 total citations
8 papers, 417 citations indexed

About

A. Bischof is a scholar working on Oncology, Molecular Biology and Cell Biology. According to data from OpenAlex, A. Bischof has authored 8 papers receiving a total of 417 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 4 papers in Molecular Biology and 3 papers in Cell Biology. Recurrent topics in A. Bischof's work include Cancer Cells and Metastasis (4 papers), Cancer Research and Treatments (2 papers) and Immune cells in cancer (2 papers). A. Bischof is often cited by papers focused on Cancer Cells and Metastasis (4 papers), Cancer Research and Treatments (2 papers) and Immune cells in cancer (2 papers). A. Bischof collaborates with scholars based in United States. A. Bischof's co-authors include Donald E. Ingber, Tadanori Mammoto, Daniel J. O’Connell, Richard L. Maas, L. Mahadevan, Ralph A. Sperling, David A. Weitz, Otger Campàs, Sean M. Hasso and Silva Krause and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Nature Methods.

In The Last Decade

A. Bischof

8 papers receiving 415 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A. Bischof United States	5	271	193	114	71	39	8	417
Ernest Latorre Spain	4	281 1.0×	166 0.9×	87 0.8×	63 0.9×	32 0.8×	5	398
Danahé Mohammed Belgium	11	282 1.0×	193 1.0×	157 1.4×	49 0.7×	52 1.3×	22	539
Franziska Wetzel Germany	8	233 0.9×	140 0.7×	127 1.1×	34 0.5×	66 1.7×	12	421
Tom Duke United Kingdom	7	306 1.1×	195 1.0×	133 1.2×	32 0.5×	47 1.2×	9	505
Feroz M. Hameed Singapore	7	308 1.1×	151 0.8×	131 1.1×	27 0.4×	65 1.7×	9	431
Jenny Fink France	7	439 1.6×	191 1.0×	224 2.0×	50 0.7×	30 0.8×	8	595
Hui Ting Ong Singapore	11	388 1.4×	236 1.2×	191 1.7×	61 0.9×	25 0.6×	25	610
Monika E. Dolega France	14	272 1.0×	410 2.1×	108 0.9×	106 1.5×	31 0.8×	19	585
Valérie Choesmel-Cadamuro France	6	385 1.4×	111 0.6×	225 2.0×	67 0.9×	34 0.9×	7	514

Countries citing papers authored by A. Bischof

Since Specialization

Citations

This map shows the geographic impact of A. Bischof's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Bischof with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Bischof more than expected).

Fields of papers citing papers by A. Bischof

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Bischof. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Bischof. The network helps show where A. Bischof may publish in the future.

Co-authorship network of co-authors of A. Bischof

This figure shows the co-authorship network connecting the top 25 collaborators of A. Bischof. A scholar is included among the top collaborators of A. Bischof based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Bischof. A. Bischof is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

Duliège, Anne‐Marie, Stefan Sleijfer, A. Bischof, et al.. (2015). Abstract CT223: CCX872: Pharmacodynamic study of a potent and selective CCR2 antagonist in human volunteers and plans for phase Ib trial in patients with pancreatic cancer. Cancer Research. 75(15_Supplement). CT223–CT223. 2 indexed citations

Jung, Heiyoun, A. Bischof, Karen Ebsworth, et al.. (2015). Combination therapy of chemokine receptor inhibition plus PDL-1 blockade potentiates anti-tumor effects in a murine model of breast cancer. Journal for ImmunoTherapy of Cancer. 3(S2). 15 indexed citations

Werfel, Justin, Silva Krause, A. Bischof, et al.. (2013). How Changes in Extracellular Matrix Mechanics and Gene Expression Variability Might Combine to Drive Cancer Progression. PLoS ONE. 8(10). e76122–e76122. 24 indexed citations

Campàs, Otger, Tadanori Mammoto, Sean M. Hasso, et al.. (2013). Quantifying cell-generated mechanical forces within living embryonic tissues. Nature Methods. 11(2). 183–189. 329 indexed citations

Bischof, A., Deniz Yüksel, Tadanori Mammoto, et al.. (2013). Breast cancer normalization induced by embryonic mesenchyme is mediated by extracellular matrix biglycan. Integrative Biology. 5(8). 1045–1056. 34 indexed citations

Schlingensiepen, K.-H., et al.. (2005). Targeted down regulation of TGF-beta2 in pancreatic carcinoma: A phase I/II dose escalation study to evaluate the safety and tolerability of the antisense oligonucleotide AP 12009. Journal of Clinical Oncology. 23(16_suppl). 4253–4253. 2 indexed citations

Bischof, A., et al.. (2004). TGF-β2 suppression by the antisense oligonucleotide AP 12009 as treatment for pancreatic cancer: preclinical efficacy data. Journal of Clinical Oncology. 22(14_suppl). 4106–4106. 8 indexed citations

Schlingensiepen, K.-H., et al.. (2004). 450 The TGF-beta1 antisense oligonucleotide AP 11014 for the treatment of non-small cell lung, colorectal and prostate cancer: preclinical studies. European Journal of Cancer Supplements. 2(8). 134–134. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact